- Home
- GAIN vs CMPX Comparison
GAIN vs CMPX Comparison
Compare GAIN & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GAIN
- CMPX
- Stock Information
- Founded
- GAIN 2005
- CMPX 2014
- Country
- GAIN United States
- CMPX United States
- Employees
- GAIN N/A
- CMPX N/A
- Industry
- GAIN Finance: Consumer Services
- CMPX Biotechnology: Pharmaceutical Preparations
- Sector
- GAIN Finance
- CMPX Health Care
- Exchange
- GAIN Nasdaq
- CMPX Nasdaq
- Market Cap
- GAIN 522.8M
- CMPX 576.5M
- IPO Year
- GAIN 2005
- CMPX N/A
- Fundamental
- Price
- GAIN $13.42
- CMPX $3.65
- Analyst Decision
- GAIN Buy
- CMPX Strong Buy
- Analyst Count
- GAIN 2
- CMPX 7
- Target Price
- GAIN $14.00
- CMPX $14.71
- AVG Volume (30 Days)
- GAIN 193.2K
- CMPX 1.7M
- Earning Date
- GAIN 11-06-2025
- CMPX 11-11-2025
- Dividend Yield
- GAIN 16.34%
- CMPX N/A
- EPS Growth
- GAIN 8.96
- CMPX N/A
- EPS
- GAIN 2.16
- CMPX N/A
- Revenue
- GAIN $95,028,000.00
- CMPX N/A
- Revenue This Year
- GAIN $6.54
- CMPX N/A
- Revenue Next Year
- GAIN $4.49
- CMPX N/A
- P/E Ratio
- GAIN $6.22
- CMPX N/A
- Revenue Growth
- GAIN 6.55
- CMPX N/A
- 52 Week Low
- GAIN $11.42
- CMPX $1.27
- 52 Week High
- GAIN $15.34
- CMPX $4.08
- Technical
- Relative Strength Index (RSI)
- GAIN 26.80
- CMPX 56.88
- Support Level
- GAIN $13.70
- CMPX $3.31
- Resistance Level
- GAIN $14.02
- CMPX $3.80
- Average True Range (ATR)
- GAIN 0.19
- CMPX 0.24
- MACD
- GAIN -0.03
- CMPX -0.01
- Stochastic Oscillator
- GAIN 2.85
- CMPX 70.51
About GAIN Gladstone Investment Corporation Business Development Company
Gladstone Investment Corp operates as an externally managed, closed-end, non-diversified management investment company. Its objective is to invest in debt and equity securities of established private businesses operating in the U.S. and to achieve and grow current income by investing in debt securities of established businesses; provide the stockholders with long-term capital appreciation in the value of its assets by investing in equity securities of established businesses. It focuses on investing in lower-middle-market private businesses.
About CMPX Compass Therapeutics Inc.
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371.